Parataxis definitively acquires control of Bridge Bio for KRW 25B to create Bitcoin treasury company

SilverBox Corp IV

Parataxis Holdings to invest KRW 25 billion for controlling interest in Bridge Biotherapeutics (KOSDAQ: 288330).
Post-closing, company renamed 'Parataxis Korea' and remains KOSDAQ-listed; will build Bitcoin treasury on Strategy/Metaplanet model.
Edward Chin to join board; Andrew Kim to become CEO of renamed company; James Lee to lead biotech division.
Transaction subject to shareholder approval; meeting expected in August 2025.
Parataxis also closing another fund with same strategy and launching additional vehicles.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.